AstraZeneca touts triplet inhaler Breztri's COPD win ahead of key FDA decision

The future of AstraZeneca’s three-in-one inhaler Breztri, which was previously hit with a surprising FDA rejection, was hinging on the outcome of another phase 3 trial. And the results from that trial look good.